Shadid Asem, Alobaida Saud, Binamer Yousef
Department of Dermatology, King Fahad Medical City, Riyadh.
Department of Dermatology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
Dermatol Reports. 2022 Oct 27;15(2):9566. doi: 10.4081/dr.2022.9566. eCollection 2023 Jun 7.
Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition that affects apocrine gland-bearing skin. The management of HS with biologics has expanded significantly over the past few years. Certolizumab pegol is a pegylated (polyethylene glycol) antigen-binding fragment of a recombinant humanized anti-TNF-α monoclonal antibody, which is approved for psoriasis, rheumatoid arthritis, ankylosing spondylitis, and Crohn's disease. In recent years many reports have been merging on the use of certolizumab in treating hidradenitis suppurativa. The electronic database MEDLINE was searched through PubMed in February 2022 using the following search terms: Certolizumab "[All Fields] OR" certolizumab pegol"[All Fields] AND "Hidradenitis suppurativa"[ All Fields]. The search revealed that certolizumab was used in 6 case reports to treat HS with a total of 7 patients. We can conclude that there are few cases in the literature discussing the use of certolizumab in HS, all of which, show a good and promising response with no reported side effects.
化脓性汗腺炎（HS）是一种影响顶泌汗腺皮肤的慢性炎症性皮肤病。在过去几年中，使用生物制剂治疗HS的情况有了显著扩展。赛妥珠单抗是一种聚乙二醇化的重组人源化抗TNF-α单克隆抗体的抗原结合片段，已被批准用于治疗银屑病、类风湿性关节炎、强直性脊柱炎和克罗恩病。近年来，有许多关于赛妥珠单抗治疗化脓性汗腺炎的报道不断涌现。2022年2月通过PubMed对电子数据库MEDLINE进行了检索，使用了以下检索词：赛妥珠单抗“[所有字段]或”聚乙二醇化赛妥珠单抗“[所有字段]以及”化脓性汗腺炎“[所有字段]。检索发现，有6篇病例报告使用赛妥珠单抗治疗HS，共涉及7名患者。我们可以得出结论，文献中讨论赛妥珠单抗治疗HS的病例很少，所有这些病例均显示出良好且有前景的反应，且未报告有副作用。
